Literature DB >> 23846288

Innate immune response to La Crosse virus infection.

Katherine G Taylor1, Karin E Peterson.   

Abstract

Viral encephalitis represents a significant, and costly, public health threat particularly for high-risk pediatric populations. An emerging mosquito-borne pathogen endemic to the United States, La Crosse virus (LACV) is one of the most common causes of viral encephalitis in children in the United States. However, no licensed therapeutics or vaccines currently exist for treatment. Hampering development efforts, the host response to LACV and its role in disease pathogenesis has only recently been examined. In this review, we discuss the current understanding of innate immune response in the context of viral pathogenesis and host susceptibility to LACV. In addition, we address the need for a clearer understanding of the early host-virus interactions in LACV infections as it relates to viral pathogenesis in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23846288     DOI: 10.1007/s13365-013-0186-6

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  57 in total

1.  Interferon antagonist NSs of La Crosse virus triggers a DNA damage response-like degradation of transcribing RNA polymerase II.

Authors:  Paul Verbruggen; Marius Ruf; Gjon Blakqori; Anna K Överby; Martin Heidemann; Dirk Eick; Friedemann Weber
Journal:  J Biol Chem       Date:  2010-11-30       Impact factor: 5.157

2.  The extracellular domain of La Crosse virus G1 forms oligomers and undergoes pH-dependent conformational changes.

Authors:  A Pekosz; F González-Scarano
Journal:  Virology       Date:  1996-11-01       Impact factor: 3.616

3.  Mechanisms of bunyavirus virulence. Comparative pathogenesis of a virulent strain of La Crosse and an avirulent strain of Tahyna virus.

Authors:  R Janssen; F Gonzalez-Scarano; N Nathanson
Journal:  Lab Invest       Date:  1984-04       Impact factor: 5.662

4.  An avirulent G1 glycoprotein variant of La Crosse bunyavirus with defective fusion function.

Authors:  F Gonzalez-Scarano; R S Janssen; J A Najjar; N Pobjecky; N Nathanson
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

5.  Pathology of La Crosse virus infection in humans.

Authors:  B Kalfayan
Journal:  Prog Clin Biol Res       Date:  1983

6.  Induction of apoptosis by La Crosse virus infection and role of neuronal differentiation and human bcl-2 expression in its prevention.

Authors:  A Pekosz; J Phillips; D Pleasure; D Merry; F Gonzalez-Scarano
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

7.  Sensitivities of neurotropic arboviruses to human interferon.

Authors:  J P Luby
Journal:  J Infect Dis       Date:  1975-10       Impact factor: 5.226

8.  La Crosse bunyavirus nonstructural protein NSs serves to suppress the type I interferon system of mammalian hosts.

Authors:  Gjon Blakqori; Sophie Delhaye; Matthias Habjan; Carol D Blair; Irma Sánchez-Vargas; Ken E Olson; Ghassem Attarzadeh-Yazdi; Rennos Fragkoudis; Alain Kohl; Ulrich Kalinke; Siegfried Weiss; Thomas Michiels; Peter Staeheli; Friedemann Weber
Journal:  J Virol       Date:  2007-03-07       Impact factor: 5.103

9.  Chemotactic and inflammatory responses in the liver and brain are associated with pathogenesis of Rift Valley fever virus infection in the mouse.

Authors:  Kimberly K Gray; Melissa N Worthy; Terry L Juelich; Stacy L Agar; Allison Poussard; Dan Ragland; Alexander N Freiberg; Michael R Holbrook
Journal:  PLoS Negl Trop Dis       Date:  2012-02-28

10.  Assessing risk in focal arboviral infections: are we missing the big or little picture?

Authors:  Andrew D Haddow; Carl J Jones; Agricola Odoi
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

View more
  7 in total

1.  Oropouche virus infection and pathogenesis are restricted by MAVS, IRF-3, IRF-7, and type I interferon signaling pathways in nonmyeloid cells.

Authors:  Jose Luiz Proenca-Modena; Renata Sesti-Costa; Amelia K Pinto; Justin M Richner; Helen M Lazear; Tiffany Lucas; Jennifer L Hyde; Michael S Diamond
Journal:  J Virol       Date:  2015-02-25       Impact factor: 5.103

2.  Toscana virus infects dendritic and endothelial cells opening the way for the central nervous system.

Authors:  Maria Grazia Cusi; Claudia Gandolfo; Chiara Terrosi; Gianni Gori Savellini; Giuseppe Belmonte; Clelia Miracco
Journal:  J Neurovirol       Date:  2015-10-28       Impact factor: 3.739

3.  La Crosse virus: a scoping review of the global evidence.

Authors:  S Harding; J Greig; M Mascarenhas; I Young; L A Waddell
Journal:  Epidemiol Infect       Date:  2018-12-05       Impact factor: 2.451

4.  Differences in neuroinvasion and protective innate immune pathways between encephalitic California Serogroup orthobunyaviruses.

Authors:  Alyssa B Evans; Clayton W Winkler; Karin E Peterson
Journal:  PLoS Pathog       Date:  2022-03-04       Impact factor: 6.823

5.  Prion Strain Differences in Accumulation of PrPSc on Neurons and Glia Are Associated with Similar Expression Profiles of Neuroinflammatory Genes: Comparison of Three Prion Strains.

Authors:  James A Carroll; James F Striebel; Alejandra Rangel; Tyson Woods; Katie Phillips; Karin E Peterson; Brent Race; Bruce Chesebro
Journal:  PLoS Pathog       Date:  2016-04-05       Impact factor: 6.823

Review 6.  Throw out the Map: Neuropathogenesis of the Globally Expanding California Serogroup of Orthobunyaviruses.

Authors:  Alyssa B Evans; Karin E Peterson
Journal:  Viruses       Date:  2019-08-29       Impact factor: 5.048

Review 7.  Orthobunyaviruses: recent genetic and structural insights.

Authors:  Richard M Elliott
Journal:  Nat Rev Microbiol       Date:  2014-09-08       Impact factor: 60.633

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.